Finasteride Clinical Guidelines

Efficacy in Benign Prostatic Hyperplasia (BPH)

Finasteride 5 mg daily reduces prostate volume, improves peak urinary flow, and lowers BPH symptom scores, achieving an average 3‑point improvement on the AUA Symptom Index in men with enlarged prostates【1】【2】【3】.
The same dose decreases the risk of acute urinary retention by approximately 67 % and reduces the need for BPH‑related surgery by 64‑67 %【1】【4】.
Benefits are greater in patients with larger prostate size or higher serum PSA levels, reflecting a higher baseline risk of disease progression【1】【3】【4】.

Finasteride is indicated only for men with objectively confirmed prostatic enlargement; it provides no benefit for men with lower‑urinary‑tract symptoms without an enlarged gland【1】【2】【3】【4】.

After 12 months of therapy, PSA values should be multiplied by 2 to offset the ≈50 % reduction caused by finasteride, facilitating accurate prostate‑cancer screening【5】【6】.
This adjustment is applicable to both the 1 mg (hair‑loss) and 5 mg (BPH) doses because each lowers PSA by roughly half after one year【5】【6】.
By three years of continuous use, PSA decline may exceed 50 %; a multiplier of 2.3 is recommended for the finasteride arm【5】【6】.
Although finasteride lowers PSA, it does not obscure PSA‑based detection of prostate cancer【1】【3】【4】.

Adding an alpha‑blocker (e.g., doxazosin) to finasteride 5 mg daily lowers the overall risk of BPH progression to 67 %, compared with 34 % for finasteride alone and 39 % for the alpha‑blocker alone【1】【3】【4】.
The combination also reduces the incidence of acute urinary retention by 79 % versus 67 % with finasteride monotherapy【1】【3】【4】.
Men with larger prostates or higher PSA values derive the greatest incremental benefit from combination therapy【1】【4】.

Sexual dysfunction (erectile dysfunction, decreased libido, reduced ejaculate volume) occurs in 2‑4 % more patients receiving finasteride compared with placebo【5】【6】.
In the first year, 3.7‑8.1 % of men experience sexual adverse effects, which are generally reversible and become uncommon after the initial year of treatment【1】.
The magnitude of sexual‑function decline (≈3.2 points on a 0‑100 scale) is smaller than the natural age‑related change (≈1.3 points per year)【5】【6】.

In postmenopausal women, finasteride 2.5‑5 mg daily can improve female‑pattern hair loss, whereas a 1 mg dose shows no advantage over placebo【7】【8】【9】.
A retrospective series reported that 2.5 mg daily produced slight improvement in ~30 % and significant improvement in ~65 % of postmenopausal patients【7】【8】【9】.
Finasteride is contraindicated in pregnancy; women of child‑bearing potential must use reliable contraception because of teratogenic risk to male fetuses【8】.
Limited evidence suggests a 1.25 mg daily dose may be effective in premenopausal women under 50 years, but hyperandrogenic young women do not experience a meaningful benefit【7】【8】【9】.

Sustained clinical benefit for BPH requires long‑term daily finasteride therapy; efficacy has been demonstrated over 4‑5 year follow‑up periods【1】【4】.

All statements are based on peer‑reviewed evidence and reflect the strength of data reported in the cited sources.